Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Lian Xiang Luo; Xing Xing Fan; Ying Li; Xia Peng; Yin Chun Ji; Wendy Wen Luan Hsiao; Liang Liu; Elaine Lai Han Leung; Xiao Jun Yao

doi:10.1039/c6md00643d

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Lian Xiang Luo, Xing Xing Fan, Ying Li, Xia Peng, Yin Chun Ji, Wendy Wen Luan Hsiao, Liang Liu, Elaine Lai Han Leung, Xiao Jun Yao

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

Original language	English (US)
Pages (from-to)	621-624
Number of pages	4
Journal	MedChemComm
Volume	8
Issue number	3
DOIs	https://doi.org/10.1039/c6md00643d
State	Published - 2017
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Pharmaceutical Science
Drug Discovery
Organic Chemistry

Access to Document

10.1039/c6md00643d

Cite this

@article{f58eb92c6f2a423eb7f8e08684e1f62b,

title = "Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells",

abstract = "Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.",

author = "Luo, {Lian Xiang} and Fan, {Xing Xing} and Ying Li and Xia Peng and Ji, {Yin Chun} and Hsiao, {Wendy Wen Luan} and Liang Liu and Leung, {Elaine Lai Han} and Yao, {Xiao Jun}",

note = "Publisher Copyright: {\textcopyright} The Royal Society of Chemistry.",

year = "2017",

doi = "10.1039/c6md00643d",

language = "English (US)",

volume = "8",

pages = "621--624",

journal = "MedChemComm",

issn = "2040-2503",

publisher = "Royal Society of Chemistry",

number = "3",

}

TY - JOUR

T1 - Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

AU - Luo, Lian Xiang

AU - Fan, Xing Xing

AU - Li, Ying

AU - Peng, Xia

AU - Ji, Yin Chun

AU - Hsiao, Wendy Wen Luan

AU - Liu, Liang

AU - Leung, Elaine Lai Han

AU - Yao, Xiao Jun

PY - 2017

Y1 - 2017

N2 - Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

AB - Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=85016102959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016102959&partnerID=8YFLogxK

U2 - 10.1039/c6md00643d

DO - 10.1039/c6md00643d

M3 - Article

AN - SCOPUS:85016102959

SN - 2040-2503

VL - 8

SP - 621

EP - 624

JO - MedChemComm

JF - MedChemComm

IS - 3

ER -

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this